Evidence map›Paper›PMID 30255543›Full record

ArticleBJU international2019

Modulatory effects of intravesical P2X2/3 purinergic receptor inhibition on lower urinary tract electromyographic properties and voiding function of female rats with moderate or severe spinal cord injury.

Betsy H Salazar, Kristopher A Hoffman, Chuan Zhang, Yingchun Zhang, Yolanda Cruz, Timothy B Boone, Alvaro Munoz

Abstract read
In one paragraph

Article in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Betsy H SalazarRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.
Kristopher A HoffmanRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.
Chuan ZhangRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.
Yingchun ZhangRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.
Yolanda CruzCentro Tlaxcala de Biología de la Conducta, Universidad Autónoma de Tlaxcala, Tlaxcala, Mexico.
Timothy B BooneRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.
Alvaro MunozRegenerative Medicine and Tissue Engineering Program-Urology, Houston Methodist Research Institute, Houston, TX,, USA.ORCID 0000-0002-5726-0810

Funding

Electromechanical Modeling Approach in Assessing Female SUIR00DK082644 · NIDDK · UNIVERSITY OF HOUSTON · PI ZHANG, YINGCHUN · 2013 to 2015
$690k
Electromechanical Modeling Approach in Assessing Female SUIK99DK082644 · NIDDK · UNIVERSITY OF MINNESOTA · PI ZHANG, YINGCHUN · 2010 to 2011
$180k
NIDDK NIH HHS K99 DK082644NIDDK NIH HHS R00 DK082644
6 · The paper itself

Abstract

objectivesTo evaluate the role that intravesical P2X2/3 purinergic receptors (P2X2/3Rs) play in early and advanced neurogenic lower urinary tract (LUT) dysfunction after contusion spinal cord injury (SCI) in female rats. MATERIALS AND

methodsFemale Sprague-Dawley rats received a thoracic Th8/Th9 spinal cord contusion with either force of 100 kDy (cN); moderate) or 150 kDy (cN; severe); Sham rats had no injury. Evaluations on urethane-anesthetised rats were conducted at either 2 or 4 weeks after SCI. LUT electrical signals and changes in bladder pressure were simultaneously recorded using cystometry and a set of custom-made flexible microelectrodes, before and after intravesical application of the P2X2/3R antagonist AF-353 (10 μM), to determine the contribution of P2X2/3R-mediated LUT modulation.

resultsSevere SCI significantly increased bladder contraction frequency, and reduced both bladder pressure amplitude and intraluminal-pressure high-frequency oscillations (IPHFO). Intravesical P2X2/3R inhibition did not modify bladder pressure or IPHFO in the Sham and moderate-SCI rats, although did increase the intercontractile interval (ICI). At 2 weeks after SCI, the Sham and moderate-SCI rats had significant LUT electromyographic activity during voiding, with a noticeable reduction in LUT electrical signals seen at 4 weeks after SCI. Intravesical inhibition of P2X2/3R increased the ICI in the Sham and moderate-SCI rats at both time-points, but had no effect on rats with severe SCI. The external urethral sphincter (EUS) showed strong and P2X2/3R-independent electrical signals in the Sham and moderate-SCI rats in the early SCI stage. At 4 weeks after SCI, the responsiveness of the EUS was significantly attenuated, independently of SCI intensity.

conclusionsThis study shows that electrophysiological properties of the LUT are progressively impaired depending on SCI intensity and that intravesical P2X2/3R inhibition can attenuate electrical activity in the neurogenic LUT at early, but not at semi-chronic SCI. This translational study should be useful for planning clinical evaluations.

Indexed as

Administration, IntravesicalAnimalsDisease Models, AnimalElectromyographyFemalePhenyl EthersPurinergic P2X Receptor AntagonistsPyrimidinesRatsRats, Sprague-DawleySignal TransductionSpinal Cord InjuriesUrethraUrinary Bladder, NeurogenicUrination5-(5-iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diaminePhenyl EthersPurinergic P2X Receptor AntagonistsPyrimidinescystometryelectromyographylower urinary tractP2X3, P2X2 purinergic receptorspinal cord injury

Identifiers

PMID30255543
PMCPMC6715153

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.